al-Kattan K, Sepsas E, Townsend E R, Fountain S W
Department of Thoracic Surgery, Harefield Hospital, Uxbridge, Middlesex, UK.
Thorax. 1996 Dec;51(12):1266-9. doi: 10.1136/thx.51.12.1266.
Survival following pulmonary resection for primary lung cancer is considered to be principally dependent on the clinical stage of the disease. A study was undertaken to verify this and to identify other contributing factors.
The case records of all patients who underwent surgery for lung cancer over a two year period between January 1987 and December 1988 were reviewed retrospectively.
One hundred and forty-seven lobectomies and 60 pneumonectomies were performed with 2.8% and 5.3% operative mortality, respectively. Squamous carcinoma was the commonest pathology (60%) followed by adenocarcinoma (30%). The overall five year survival was 45.5% (95% CI 44.1% to 57.9%). There were 123 patients with stage I disease, 40 with stage II, and 37 in stage IIIa with five year survival of 59.4% (95% CI 50.8% to 68%), 30% (95% CI 15.9% to 44.1%), and 16.2% (95% CI 3.5% to 31%), respectively. There were no differences in survival with respect to sex, extent of resection, or cell type. In patients with stage II disease the five year survival of those with T1 lesions (50%, 95% CI 37.3% to 62.9%) was better than those with T2 (28.1%, 95% CI 16.9% to 39.3%). Of eight patients over the age of 70 with stage IIIa disease none survived more than 24 months.
Stage at operation is the most accurate predictor of long term survival in early lung cancer and surgery remains an effective treatment, particularly in stage I and II disease. Further study is needed to assess the prognostic value of subdividing stage II disease into T1 and T2 lesions. Major resection for locally advanced disease in older patients may be relatively ineffective.
原发性肺癌肺切除术后的生存率主要被认为取决于疾病的临床分期。开展了一项研究以验证这一点并确定其他影响因素。
回顾性分析了1987年1月至1988年12月这两年间所有接受肺癌手术患者的病历。
共进行了147例肺叶切除术和60例全肺切除术,手术死亡率分别为2.8%和5.3%。鳞状细胞癌是最常见的病理类型(60%),其次是腺癌(30%)。总体五年生存率为45.5%(95%可信区间44.1%至57.9%)。有123例I期疾病患者,40例II期患者,37例IIIa期患者,其五年生存率分别为59.4%(95%可信区间50.8%至68%)、30%(95%可信区间15.9%至44.1%)和16.2%(95%可信区间3.5%至31%)。在生存率方面,性别、切除范围或细胞类型之间无差异。在II期疾病患者中,T1病变患者的五年生存率(50%,95%可信区间37.3%至62.9%)优于T2病变患者(28.1%,95%可信区间16.9%至39.3%)。8例年龄超过70岁的IIIa期疾病患者中,无一例存活超过24个月。
手术分期是早期肺癌长期生存最准确的预测指标,手术仍然是一种有效的治疗方法,特别是在I期和II期疾病中。需要进一步研究以评估将II期疾病细分为T1和T2病变的预后价值。老年患者局部晚期疾病的大手术可能相对无效。